Freeslate enters into strategic partnership with J&J
Freeslate has entered into a strategic partnership with Johnson and Johnson (J&J) to provide the pharma with integrated workflows, software and research services until 2012.
J&J will make use of Freeslate’s modular CM3 platform for small molecule drug development. Also, the platform can be used for biologics development and formulation.
The laboratory execution and analysis (LEA) software suite will power these tools and integrate a number of existing workflows.
Freeslate was formed earlier this year when Symyx divested its high productivity research unit. The company aims to enable “step-change gains in productivity and innovation by providing researchers with increased experimental capacity and faster decision-making”.
